Virax Biolabs (VRAX) Debt Ratio (2023 - 2026)
Virax Biolabs (VRAX) posted quarterly Debt Ratio of 0.0 for Q1 2026, down 32.29% year-over-year from 0.01 in Q1 2025, and down 32.29% quarter-over-quarter from 0.01 in Q1 2025.
Virax Biolabs (VRAX) Debt Ratio (2023 - 2026) Analysis & Trends
Virax Biolabs' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.0 for Q1 2026.
- In Q1 2026, Debt Ratio fell 32.29% year-over-year to 0.0; the TTM figure through Mar 2026 stood at 0.0 (down 32.29% YoY), while the FY2026 annual figure was 0.0, down 32.29% from the prior year.
- Debt Ratio for Q1 2026 stood at 0.0, down from 0.01 in the prior quarter.
- The five-year high for Debt Ratio was 0.01 in Q1 2023, with the low at 0.0 in Q1 2026.
- The 3-year median for Debt Ratio is 0.01 (2025), against an average of 0.01.
- Peak annual rise in Debt Ratio reached 32.29% in 2026, while the deepest fall reached 32.29% in 2026.
- Virax Biolabs' Debt Ratio stood at 0.01 in 2023, then sank by 66.11% to 0.01 in 2025, then sank by 32.29% to 0.0 in 2026.
- Business Quant data shows VRAX's Debt Ratio at 0.0 in Q1 2026, 0.01 in Q1 2025, and 0.01 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 0.47 |
| 10 | Virax Biolabs | 1.26 Mn | -5.17 Mn | - | 0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Mar 31, 2025 | 0.01 |
| Mar 31, 2023 | 0.01 |